Retatrutide cuts weight in a phase 3 trial
In an 80-week randomized trial of adults with obesity but no diabetes, weekly retatrutide produced larger weight loss than placebo and improved knee pain and sleep-apnea events in prespecified subgroups; gastrointestinal adverse events were common, and long-term use remains an open question.
The 60-second version
In a phase 3 trial, weekly retatrutide produced substantially more average weight loss than placebo over 80 weeks, with additional subgroup improvements in knee pain and sleep-apnea events.
Key points
- 2,339 adults with obesity but no diabetes received 4, 9 or 12 mg retatrutide, or placebo.
- Mean weight change was −23.7% at 9 mg and −25.0% at 12 mg, versus −3.9% with placebo.
- Participants with knee osteoarthritis or obstructive sleep apnea also improved on prespecified outcomes.
- Gastrointestinal adverse events were the most common; the trial was funded by Eli Lilly.
- Long-term safety, weight maintenance after stopping and real-world access remain unanswered.
Verdict. This is strong evidence of 80-week weight reduction, not proof of a universal or lifelong treatment plan.
The trialA once-weekly injection was tested for 80 weeks
TRIUMPH-1 assigned 2,339 adults with obesity and no diabetes to weekly retatrutide at 4, 9 or 12 milligrams, or to placebo. The trial was randomized and double-blind, so neither participants nor investigators knew the assigned treatment during the main comparison.
WeightThe largest doses produced the largest average losses
At week 80, mean body-weight change was minus 17.6% with 4 mg, minus 23.7% with 9 mg and minus 25.0% with 12 mg. The placebo group changed by minus 3.9%. The headline numbers are averages across groups, not individual guarantees.
| Retatrutide 4 mg | −17.6% mean weight change at week 80 |
|---|---|
| Retatrutide 9 mg | −23.7%; 19.8 percentage points beyond placebo |
| Retatrutide 12 mg | −25.0%; 21.0 percentage points beyond placebo |
| Placebo | −3.9% mean weight change |
Related conditionsKnee pain and sleep-apnea events also improved in subgroups
The study prespecified two relevant subgroups. Among 574 participants with knee osteoarthritis, WOMAC pain scores improved more with 9 or 12 mg than with placebo. Among 243 participants with obstructive sleep apnea, apnea-hypopnea events per hour fell more with retatrutide. These are meaningful signals, but they remain subgroup results from one trial.
| Knee osteoarthritis | 574 participants; 9 and 12 mg improved WOMAC pain more than placebo |
|---|---|
| Obstructive sleep apnea | 243 participants; 9 and 12 mg reduced apnea-hypopnea events more than placebo |
SafetyThe common downside was gastrointestinal
Gastrointestinal adverse events were the most common in the abstract. A short report cannot replace the full safety tables, and an 80-week trial cannot answer every question about multi-year use, discontinuation or weight regain after stopping.
What it meansStrong evidence for weight reduction, not a finished treatment plan
- What is supported: retatrutide caused larger average weight reductions than placebo over 80 weeks in adults with obesity without diabetes.
- What is promising: the trial also found better knee-pain and sleep-apnea outcomes in prespecified subgroups.
- What remains open: long-term safety, weight maintenance after stopping, generalizability and access.
- What to do: treatment decisions should follow a clinician's assessment, not a percentage copied from a headline.
The result is large, but the honest claim is narrow: this trial shows substantial average weight loss over 80 weeks.